X4 PHARMACEUTICALS, INC Net Income (Loss) Available to Common Stockholders, Basic
X4 PHARMACEUTICALS, INC (XFOR) reported Net Income (Loss) Available to Common Stockholders, Basic of -$37.45 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2025-03-26
- X4 PHARMACEUTICALS, INC net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$51.77M.
- X4 PHARMACEUTICALS, INC net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$19.13M.
- X4 PHARMACEUTICALS, INC net income (loss) available to common stockholders, basic for the quarter ending 2023-09-30 was -$2.31M.
- X4 PHARMACEUTICALS, INC net income (loss) available to common stockholders, basic for the quarter ending 2023-06-30 was -$55.71M.
- X4 PHARMACEUTICALS, INC net income (loss) available to common stockholders, basic for fiscal 2024 was -$37.45M.
- X4 PHARMACEUTICALS, INC net income (loss) available to common stockholders, basic for fiscal 2023 was -$101.17M.
- X4 PHARMACEUTICALS, INC net income (loss) available to common stockholders, basic for fiscal 2022 was -$96.41M.
- X4 PHARMACEUTICALS, INC net income (loss) available to common stockholders, basic for fiscal 2021 was -$102.64M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$37.45M 10-K · filed 2025-03-26 | |||||||
| 2024-03-31 | -$51.77M 10-Q · filed 2024-05-07 | -$70.90M derived: sum of 2 quarters · filed 2025-03-26 | -$73.20M derived: sum of 3 quarters · filed 2025-03-26 | -$128.91M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-12-31 | -$19.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$21.43M derived: sum of 2 quarters · filed 2025-03-26 | -$77.15M derived: sum of 3 quarters · filed 2025-03-26 | -$101.17M 10-K · filed 2025-03-26 | ||||
| 2023-09-30 | -$2.31M 10-Q · filed 2023-11-09 | -$58.02M derived: sum of 2 quarters · filed 2023-11-09 | -$82.04M 10-Q · filed 2023-11-09 | -$111.14M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-06-30 | -$55.71M 10-Q · filed 2023-08-10 | -$79.73M 10-Q · filed 2023-08-10 | -$108.84M derived: sum of 3 quarters · filed 2025-03-26 | -$130.71M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2023-03-31 | -$24.02M 10-Q · filed 2024-05-07 | -$53.12M derived: sum of 2 quarters · filed 2025-03-26 | -$75.00M derived: sum of 3 quarters · filed 2025-03-26 | -$96.21M derived: sum of 4 quarters · filed 2025-03-26 | ||||
| 2022-12-31 | -$29.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$50.98M derived: sum of 2 quarters · filed 2025-03-26 | -$72.19M derived: sum of 3 quarters · filed 2025-03-26 | -$96.41M 10-K · filed 2025-03-26 | ||||
| 2022-09-30 | -$21.87M 10-Q · filed 2023-11-09 | -$43.09M derived: sum of 2 quarters · filed 2023-11-09 | -$67.31M 10-Q · filed 2023-11-09 | -$103.22M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-06-30 | -$21.21M 10-Q · filed 2023-08-10 | -$45.44M 10-Q · filed 2023-08-10 | -$81.35M derived: sum of 3 quarters · filed 2024-03-21 | -$101.52M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2022-03-31 | -$24.22M 10-Q · filed 2023-05-04 | -$60.13M derived: sum of 2 quarters · filed 2024-03-21 | -$80.31M derived: sum of 3 quarters · filed 2024-03-21 | -$99.95M derived: sum of 4 quarters · filed 2024-03-21 | ||||
| 2021-12-31 | -$35.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$56.09M derived: sum of 2 quarters · filed 2024-03-21 | -$75.72M derived: sum of 3 quarters · filed 2024-03-21 | -$102.64M 10-K · filed 2024-03-21 | ||||
| 2021-09-30 | -$20.18M 10-Q · filed 2022-11-03 | -$39.81M derived: sum of 2 quarters · filed 2022-11-03 | -$66.73M 10-Q · filed 2022-11-03 | -$85.13M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-06-30 | -$19.64M 10-Q · filed 2022-08-04 | -$46.55M 10-Q · filed 2022-08-04 | -$64.95M derived: sum of 3 quarters · filed 2023-03-21 | -$82.40M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2021-03-31 | -$26.91M 10-Q · filed 2022-05-12 | -$45.31M derived: sum of 2 quarters · filed 2023-03-21 | -$62.76M derived: sum of 3 quarters · filed 2023-03-21 | -$77.91M derived: sum of 4 quarters · filed 2023-03-21 | ||||
| 2020-12-31 | -$18.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | -$35.85M derived: sum of 2 quarters · filed 2023-03-21 | -$50.99M derived: sum of 3 quarters · filed 2023-03-21 | -$62.13M 10-K · filed 2023-03-21 | ||||
| 2020-09-30 | -$17.45M 10-Q · filed 2021-11-04 | -$32.59M derived: sum of 2 quarters · filed 2021-11-04 | -$43.73M 10-Q · filed 2021-11-04 | -$54.57M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-06-30 | -$15.14M 10-Q · filed 2021-08-03 | -$26.28M 10-Q · filed 2021-08-03 | -$37.12M derived: sum of 3 quarters · filed 2022-03-17 | -$54.83M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2020-03-31 | -$11.14M 10-Q · filed 2021-05-06 | -$21.98M derived: sum of 2 quarters · filed 2022-03-17 | -$39.69M derived: sum of 3 quarters · filed 2022-03-17 | -$53.07M derived: sum of 4 quarters · filed 2022-03-17 | ||||
| 2019-12-31 | -$10.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$28.55M derived: sum of 2 quarters · filed 2022-03-17 | -$41.93M derived: sum of 3 quarters · filed 2022-03-17 | -$53.40M 10-K · filed 2022-03-17 | ||||
| 2019-09-30 | -$17.71M 10-Q · filed 2020-11-05 | -$31.10M derived: sum of 2 quarters · filed 2020-11-05 | -$42.56M 10-Q · filed 2020-11-05 | -$54.60M derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-06-30 | -$13.38M 10-Q · filed 2020-08-04 | -$24.85M 10-Q · filed 2020-08-04 | -$36.89M derived: sum of 3 quarters · filed 2021-03-19 | -$46.24M derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2019-03-31 | -$11.46M 10-Q · filed 2020-05-07 | -$23.50M derived: sum of 2 quarters · filed 2021-03-19 | -$32.86M derived: sum of 3 quarters · filed 2021-03-19 | -$39.66M derived: sum of 4 quarters · filed 2021-03-19 | ||||
| 2018-12-31 | -$12.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | -$21.40M derived: sum of 2 quarters · filed 2021-03-19 | -$28.20M derived: sum of 3 quarters · filed 2021-03-19 | -$36.31M 10-K · filed 2021-03-19 | -$43.02M 10-K · filed 2019-03-11 | |||
| 2018-09-30 | -$9.36M 10-Q · filed 2019-11-07 | -$10.90M 10-Q · filed 2018-11-09 | -$16.16M derived: sum of 2 quarters · filed 2019-11-07 | -$24.27M 10-Q · filed 2019-11-07 | -$33.66M 10-Q · filed 2018-11-09 | -$26.54M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | -$6.80M 10-Q · filed 2019-08-07 | -$12.13M 10-Q · filed 2018-08-13 | -$14.91M 10-Q · filed 2019-08-07 | -$22.76M 10-Q · filed 2018-08-13 | -$17.18M derived: sum of 3 quarters · filed 2020-03-12 | -$28.80M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | -$8.11M 10-Q · filed 2019-05-15 | -$10.63M 10-Q · filed 2018-05-10 | -$10.38M derived: sum of 2 quarters · filed 2020-03-12 | -$21.99M derived: sum of 3 quarters · filed 2020-03-12 | -$27.71M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | -$2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | -$13.88M derived: sum of 2 quarters · filed 2020-03-12 | -$19.60M derived: sum of 3 quarters · filed 2020-03-12 | -$24.99M 10-K · filed 2020-03-12 | -$33.92M 10-K · filed 2019-03-11 | |||
| 2017-09-30 | -$11.62M 10-Q · filed 2018-11-09 | -$17.33M derived: sum of 2 quarters · filed 2018-11-09 | -$22.73M 10-Q · filed 2018-11-09 | |||||
| 2017-06-30 | -$5.72M 10-Q · filed 2018-08-13 | -$11.11M 10-Q · filed 2018-08-13 | ||||||
| 2017-03-31 | -$5.39M 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | -$23.00M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |